Another EpiPen Is Now on the Market

Teva Pharmaceuticals has finally launched its generic version of Mylan’s EpiPen.  The Petah, Tikvah, Israel-based company’s emergency allergy shot will be priced at $300 – the same as Mylan’s generic. Teva received approval for its version of EpiPen in August. The generic will be available in limited supply and the company will launch a lower-dose - the EpiPen Jr. sometime next year, the company said. “We’re pleased to provide access to Epinephrine Injection (Auto-Injector) for patients who may experience life-threatening allergic emergencies and we’re fully dedicated toward ensuring additional supply in 2019,” Brendan O’Grady, EVP and Head of North America Commercial at Teva Pharmaceutical, said in a release. Epinephrine Injection (Auto-Injector) is a prescription medicine in a disposable, pre-filled automatic injection device (auto-injector) used to treat life-threatening, allergic emergencies including anaphylaxis in people who are at risk for or have a history of serious allergic emergencies. Each device contains a single dose of epinephrine. Why this News is Significant Teva launching its generic takes some of the pressure off since Mylan’s product had a shortage earlier this year. Back in May, Mylan said it had alerted FDA that there could be trouble in getting the EpiPen prescript...
Source: MDDI - Category: Medical Devices Authors: Tags: Business Source Type: news